Correlation Between Conduit Pharmaceuticals and Northwest Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Conduit Pharmaceuticals and Northwest Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Conduit Pharmaceuticals and Northwest Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Conduit Pharmaceuticals and Northwest Biotherapeutics, you can compare the effects of market volatilities on Conduit Pharmaceuticals and Northwest Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Conduit Pharmaceuticals with a short position of Northwest Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Conduit Pharmaceuticals and Northwest Biotherapeutics.

Diversification Opportunities for Conduit Pharmaceuticals and Northwest Biotherapeutics

0.15
  Correlation Coefficient

Average diversification

The 3 months correlation between Conduit and Northwest is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Conduit Pharmaceuticals and Northwest Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Northwest Biotherapeutics and Conduit Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Conduit Pharmaceuticals are associated (or correlated) with Northwest Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Northwest Biotherapeutics has no effect on the direction of Conduit Pharmaceuticals i.e., Conduit Pharmaceuticals and Northwest Biotherapeutics go up and down completely randomly.

Pair Corralation between Conduit Pharmaceuticals and Northwest Biotherapeutics

Assuming the 90 days horizon Conduit Pharmaceuticals is expected to generate 5.61 times more return on investment than Northwest Biotherapeutics. However, Conduit Pharmaceuticals is 5.61 times more volatile than Northwest Biotherapeutics. It trades about 0.13 of its potential returns per unit of risk. Northwest Biotherapeutics is currently generating about -0.06 per unit of risk. If you would invest  1.32  in Conduit Pharmaceuticals on December 5, 2024 and sell it today you would earn a total of  0.17  from holding Conduit Pharmaceuticals or generate 12.88% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy90.48%
ValuesDaily Returns

Conduit Pharmaceuticals  vs.  Northwest Biotherapeutics

 Performance 
       Timeline  
Conduit Pharmaceuticals 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Conduit Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Conduit Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.
Northwest Biotherapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Northwest Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy fundamental drivers, Northwest Biotherapeutics is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors.

Conduit Pharmaceuticals and Northwest Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Conduit Pharmaceuticals and Northwest Biotherapeutics

The main advantage of trading using opposite Conduit Pharmaceuticals and Northwest Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Conduit Pharmaceuticals position performs unexpectedly, Northwest Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Northwest Biotherapeutics will offset losses from the drop in Northwest Biotherapeutics' long position.
The idea behind Conduit Pharmaceuticals and Northwest Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance